Page 23 – Myeloma Academy

Diagnostic techniques and prognostic indicators

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Bossuyt X et al.Leukemia. 2017 Nov 20. doi: 10.1038/leu.2017.335. [Epub ahead of print]. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Cetin AE et al. Nat Commun. 2017 Nov 20;8(1):1613. doi: 10.1038/s41467-017-01593-2. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma. Dalla Palma B et al. Br J Haematol. 2017 Nov…

Details

November 27, 2017Diagnosing and Monitoring Myeloma, Journal, LibraryBy sarahfleming

Current treatments

Final analysis of survival outcomes in the randomized phase 3 FIRST trial. Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print]. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print]. An overview of the…

Details

November 27, 2017Journal, LibraryBy sarahfleming

Complications of myeloma and its treatments

Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…

Details

November 27, 2017Journal, Library, Management of complications & side effectsBy sarahfleming

Biology and genetics

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print]. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print]. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences…

Details

November 27, 2017Journal, Library, Management of MyelomaBy sarahfleming

IMWG Consensus of second primary malignancies in myeloma

This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.

November 2, 2017Clinical guidelines & position statements, Complications, IMWG, LibraryBy sarahfleming

IMWG Consensus criteria for response and minimal residual disease in myeloma

This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.

Read abstract

November 2, 2017Clinical guidelines & position statements, Imaging & Analysis, IMWG, LibraryBy sarahfleming

IMWG Consensus statement on the treatment of myeloma patients with high-risk cytogenetics

This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.

November 2, 2017Clinical guidelines & position statements, IMWG, Library, Management & TreatmentBy sarahfleming

IMWG Recommendations for the management of relapsed myeloma

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.

Read abstract

November 2, 2017Clinical guidelines & position statements, IMWG, Library, Management & TreatmentBy sarahfleming

IMWG Recommendations for the diagnosis and management of myeloma-related renal impairment

This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease

November 2, 2017Clinical guidelines & position statements, Complications, IMWG, LibraryBy sarahfleming

EMN Guidelines for the management of myeloma-related conditions

These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.

November 2, 2017Clinical guidelines & position statements, Complications, European Myeloma Network, LibraryBy sarahfleming

Blog